Why NPN Applications Fail: Common Deficiencies Under Canada's Natural Health Products Regulations

Health Canada’s Natural and Non-prescription Health Products Directorate has been processing NPN applications for over 20 years — and the deficiency notice is still the most common outcome of a first submission. Not because Canada’s Natural Health Products Regulations are unusually complex. But because most applications arrive with the same small set of avoidable errors that experienced reviewers recognize immediately.

The Natural Health Products Regulations (NHPR), which came into force on June 18, 2004 under the Food and Drugs Act, established a licensing framework designed to be rigorous. Products that make therapeutic claims and reach Canadian consumers should face scrutiny. But the NHPR also has precise procedural requirements that trip up applicants who treat it like a simplified pharmaceutical DIN submission. It isn’t. And the directorate’s workload — Health Canada has issued more than 85,000 Natural Product Numbers since 2004 — means reviewers don’t have latitude to assume what you meant to say.

Here’s where applications most commonly go wrong, and what to do about it before you file.

Why Health Canada Flags Your NHP Claims

The most frequent source of deficiency notices is a mismatch between the health claim printed on the label and the evidence submitted in the Product Information Form (PIF) to support it.

Under the NHPR, every claim must be substantiated. Health Canada accepts several categories of evidence: peer-reviewed clinical research, traditional use references (which require a minimum of 50 years of documented use, with at least 15 of those years in a Western context for many ingredient categories), and entries in Health Canada’s Compendium of Monographs. Which category of evidence you need depends directly on the specific claim you’re making — and the specificity of the claim determines the quality of evidence required.

Where applicants consistently stumble is using evidence that establishes mechanism of action or surrogate endpoints as support for a direct health outcome claim. Documenting that a probiotic strain “supports balanced gut flora” is a different regulatory task than claiming it “helps reduce the duration of antibiotic-associated diarrhea.” The latter requires a more substantial, controlled evidence base. Submitting studies that demonstrate the former to support the latter draws a Notice of Deficiency almost every time.

Each Notice of Deficiency pauses the official review clock. In practice, resolving one adds 30 to 90 days to your timeline, depending on how quickly your team can compile a response package. For a Class II review, which carries a 180-day target timeline, a single deficiency cycle can push your NPN approval past the nine-month mark. Multiple deficiencies — which aren’t uncommon when the original submission wasn’t thoroughly cross-checked — can stretch things considerably further.

The fix is a matter of discipline in sequencing: draft your intended claims first, identify the supporting evidence second, and verify that the evidence actually establishes what the claim asserts before building the rest of the PIF around it.

Label Deficiencies That Trigger Automatic Returns

Canadian regulators read labels carefully. So do NNHPD reviewers. Labels are among the most technically demanding components of an NHP submission and one of the most reliable sources of automatic returns.

Under NHPR Schedule 1, mandatory label elements include the product’s proper name, net quantity, recommended use or purpose, recommended conditions of use (covering route of administration, dose, dosage form, and duration of use where applicable), and all required risk information including cautions, warnings, and contra-indications. The format is prescribed, and so is the language: bilingual English and French labelling is mandatory for any product sold in Canada.

A few specific issues that generate returns more often than you’d expect:

Dose quantity mismatches. The quantity per dosage unit recorded in Section 1 of the PIF must exactly match what appears on the label. A product whose label reads “500 mg per capsule” while the PIF records “500 mg per 2-capsule serving” will receive a deficiency notice. The inconsistency is small but disqualifying.

Omitted cautions. If any of the clinical studies cited in your evidence dossier reported adverse events — even minor, transient ones — reviewers expect to see corresponding cautions on the label. Omitting study-reported adverse events from your risk information section doesn’t make them invisible to the reviewer; it signals that the label and the evidence dossier were assembled without cross-referencing each other.

Non-compliant claim language. NHP labels cannot use drug-like phrasing such as “treats,” “cures,” or “prevents disease.” Terms like “helps maintain” or “supports healthy function” are generally acceptable. Health Canada’s guidance on permissible claim language for specific categories runs to dozens of pages; reviewing it against your final label copy before submission is not optional if you want to avoid a return.

GMP Documentation Gaps in Multi-Site Supply Chains

Every NHP sold in Canada must be manufactured by a facility holding a valid Site Licence issued under the NHPR. Site licences are issued per site and per product-class activity — manufacturing, packaging, labelling, importing — and they require annual renewal. This much is widely understood.

What catches applicants off guard more often is the GMP attestation requirement within the PIF itself. Most submissions don’t require a full audit report; they require an attestation that the product was or will be manufactured in compliance with Health Canada’s Good Manufacturing Practices for Natural Health Products (guidance document GUI-0059). But that attestation must come from the right person — the qualified individual responsible for the manufacturing site or, for imported products, the importer of record — and it must reflect current conditions.

The problem compounds in multi-site supply chains. If your formulation is manufactured at Facility A, encapsulated at Facility B, and packaged at Facility C, each facility performing a regulated activity must hold a Site Licence covering that specific activity. A missing Site Licence for the encapsulation step, or an attestation signed by someone who isn’t the designated qualified individual for that facility, generates an automatic deficiency. We’ve seen this happen to experienced manufacturers simply because a contract site had let a licence lapse during renewal.

For imported NHPs, the bar is higher still. The Canadian importer — who must hold their own Site Licence — is responsible for demonstrating that the foreign manufacturer operates to GMP standards equivalent to Health Canada’s requirements. Reviewers are increasingly skeptical of bare-bones equivalency claims. Third-party audit reports from recognized bodies, or certificates of compliance referencing ISO or PIC/S standards, provide far more defensible documentation than a one-sentence attestation.

How the Compendium of Monographs Can Shorten Your Review by Three Months

If you’ve filed more than a handful of NPN applications, you know the Compendium of Monographs. If you’re newer to the NHPD licensing process, understanding how to use it strategically is the most valuable thing you can do before your next filing.

The Compendium is a database of pre-assessed ingredient profiles maintained by the NNHPD. When a product’s formulation, dose, dosage form, and claims fall entirely within a published monograph’s specifications, the submission qualifies for a Class I attestation review — a streamlined pathway with a 60-day target timeline. Compare that to 180 days for a Class II review or 300 days for Class III, and the business case for monograph alignment is obvious.

The challenge is that “falls within the monograph” means precisely that. The acceptable dose range, the source and specification of the medicinal ingredient, the permitted route of administration, and the approved health claims must all match what the monograph specifies. A product using a botanical extract standardized to a constituent percentage not contemplated by the monograph, or pairing a listed ingredient with a claim that extends beyond the monograph’s approved language, loses Class I eligibility.

We’ve seen applicants file Class I attestation submissions with formulations that are close to — but not fully within — the monograph. Sometimes the ingredient specification is almost right. Sometimes a single extra claim has been added. The result is reclassification to Class II, a new target timeline, and a three-month delay that a careful pre-submission monograph mapping exercise would have prevented.

Run every medicinal and non-medicinal ingredient against the Compendium before finalizing the formulation. If you’re adjacent to a monograph but not fully compliant, it’s usually faster to adjust the formulation or trim the claim scope than to proceed with a Class II submission.

What the Directorate Actually Rewards

NNHPD reviewers are working through high volumes with consistent standards. Submissions that are internally coherent — where the PIF’s claim section, evidence dossier, label, and GMP documentation all tell the same story using consistent terminology — move through more predictably than those requiring the reviewer to reconcile conflicting information across documents.

This sounds straightforward. But a PIF assembled in pieces, with claims drafted by marketing, evidence selected by a formulation scientist, and labels finalized by a third party who hasn’t seen the other two documents, frequently has exactly these internal contradictions. A single pre-submission review pass specifically focused on cross-document consistency catches most of them.

The NHPR framework is mature. Health Canada has issued more than 85,000 Natural Product Numbers in its lifetime. The regulatory pathway is well-documented and predictable — when you treat it systematically. Deficiency rates stay high not because the rules are unclear, but because submissions arrive without the kind of structured internal review the process rewards.

Start with your claims. Verify your evidence against each one. Map your formulation against the Compendium. Audit every document in the PIF against every other document before submission. The deficiency notice you avoid is the three months you don’t lose.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• COA Verification and Supplier Qualification for Canadian API Imports — Qalitex Laboratories provides ISO 17025-accredited testing to support NHP and pharmaceutical manufacturers with certificate of analysis verification and incoming material testing.
• EU Cosmetics Notification vs. Health Canada NHP Licensing: Key Divergences for Dual-Market Brands — Care Europe breaks down how the EU 1223/2009 framework and Canada’s NHPR differ in evidence standards, labelling requirements, and pre-market authorization for manufacturers targeting both markets.